Arkolith/Insider Trading/ORKA/Form 4

Sandler Laura Lee

Chief Operating OfficerOruka Therapeutics, Inc. (ORKA) · full profile →Form 4 · filed May 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$319K
Net Open-Market Flow
-$319K
Transactions
8
7 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)5K$7.80$39K242K
May 1, 2026Sell(S)2K$62.58$138K240K
May 1, 2026Sell(S)2K$64.15$115K238K
May 1, 2026Sell(S)300$65.10$20K238K
May 1, 2026Sell(S)400$66.06$26K237K
May 1, 2026Sell(S)200$67.16$13K237K
May 1, 2026Sell(S)100$68.48$7K237K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)5K—$085K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000907654-26-000037) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML